Technology | Cath Lab | February 07, 2018

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares

Latest versions of 0.035-inch snares offer clinical versatility in retrieving or repositioning intravascular devices for peripheral procedures

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares

February 7, 2018 — Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch of new versions of its Expro Elite and Sympro Elite Snares for manipulating interventional devices in peripheral procedures.

Both the Expro Elite and Sympro Elite Snares represent next-generation versions of the 0.035-inch interventional snares originally launched in the U.S. in 2008 by Vascular Solutions, now a wholly-owned subsidiary of Teleflex Inc.

Stewart Strong, president and general manager of the Interventional business unit of Teleflex, said both snare products feature:

  • A durable nitinol construction that retains its shape and adds strength;
  • A radiopaque gold-plated tungsten coil and tip for enhanced visibility;
  • 1:1 torque response for controlled positioning and better access to distal targets; and
  • A unique locking handle that facilitates secure capture.

The Expro Elite Snare uses a helical loop for capture in all directions. The Sympro Elite Snare uses a 90-degree loop that remains coaxial to the vessel lumen for easy capture. Both snare products feature a preassembled, one-piece design that allows rapid deployment through any 0.035-inch compatible lumen. Both the Expro Elite and Sympro Elite Snares are available in 5, 10, 15, 25 and 35 mm loop diameters for clinical versatility. Both snares are 150 cm in length and are packaged one per box.

Both snares are intended for use in the cardiovascular system and hollow viscus to retrieve and/or manipulate objects using minimally-invasive surgical procedures. Manipulation procedures include retrieval and/or repositioning of intravascular foreign objects such as coils, balloons, catheters, and/or guidewires within the cardiovascular system. The devices are not intended for use in the coronary arteries or neurovasculature.

For more information: www.teleflex.com

 

Related Content

Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
Overlay Init